Rigetti’s binding risk is validation-to-demand conversion: proving sustained, buyer-relevant performance at scale, then translating that into repeatable deployments (not one-off R&D milestones). If
GA timing slips again or follow-on
on-prem wins don’t appear after the
C-DAC reference, concentration and valuation risks compound quickly. Even with strong cash today, prolonged commercialization could force strategy changes (more services, slower roadmap) that weaken long-term
unit economics.